Crohn's DiseasePhase 3COMMIT-CDNCT06937099
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
A Phase 3 study testing Mirikizumab and Tirzepatide in people with Crohn's Disease and Obesity or Overweight, run by Eli Lilly and Company at 183 sites in 22 countries.
Trial summary
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Crohn's Disease, Obesity or Overweight
- What is being tested?
- Mirikizumab and Tirzepatide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 290 participants
- Where
- 183 sitesin 22 countries
- Study dates
- 26 Jun 2025to May 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have a confirmed diagnosis of Crohn's disease (CD) or perianal fistulizing CD
- Have obesity body mass index 30 kilograms per meter squared (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m2 to <30 kg/m²) and in the presence of at least 1 weight-related comorbid conditions:
- hypertension
- Type 2 diabetes mellitus (T2DM)
- dyslipidemia
- obstructive sleep apnea, or
Show all 11Show fewer
- cardiovascular disease.
- Have moderately to severely active CD defined by a CDAI score of at least 220 at baseline.
- Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6 for patients with ileal-colonic or ≥4 for patients with isolated ileal disease within 21 days before the first dose of study treatment.
- Participants with a history of CD for ≥8 years involving only or predominantly the colon must have documented negative results for colorectal dysplasia and cancer within 1 year prior to baseline.
- Demonstrated inadequate response, loss of response or intolerance to at least one protocol-specified conventional or advanced CD therapy
Who cannot join
- Have a current diagnosis of Ulcerative Colitis (UC), inflammatory bowel disease-unclassified (formerly known as indeterminate colitis), or primary sclerosing cholangitis.
- Have more than 2 missing segments of the following 5 segments: terminal ileum, ·right colon, transverse colon, ·left colon, and rectum.
- Currently have or are suspected to have an abscess.
- Have a stoma, ileoanal pouch, or ostomy.
- Have a history of more than 3 small bowel resections, total resection of small bowel greater than 100 centimeters (cm), diagnosis of short bowel syndrome, or any intestinal or non-intestinal intra-abdominal surgery within 3 months of baseline.
- Have a diagnosis of Type 1 Diabetes Mellitus (T1DM) or have insulin-treated T2DM.
Show all 9Show fewer
- Have a history of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening.
- Have had more than 5% body weight change in the past 3 months
- Have a current or recent acute, active infection.
Trial locations and contacts
183 sites in 22 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
183 sites in 22 countries
United States35 sites, 35 recruiting
- Recruiting
Smart Cures Clinical Research
Anaheim, California, 92806
Dennis Riff
- Recruiting
Cedars-Sinai Medical Center
Beverly Hills, California, 90211
310-423-4100
Andres Yarur
- Recruiting
Capital Digestive Care - Chevy Chase
Chevy Chase, Maryland, 20815
Erica Cohen
- Recruiting
Rush University Medical Center
Chicago, Illinois, 60612
Atsushi Sakuraba
- Recruiting
Gastroenterology Center Of The Midsouth
Cordova, Tennessee, 38018
Ziad Younes
- Recruiting
Digestive Health Specialists
Dothan, Alabama, 36301
334-836-1212
Paul Lamb
- Recruiting
Coastal Research Institute - Fayetteville
Fayetteville, North Carolina, 28304
John Poulos
- Recruiting
Gastroenterology Associates - Patewood
Greenville, South Carolina, 29607
864-451-5026
Matthew Barnes
- Recruiting
Grand Teton Research Group
Idaho Falls, Idaho, 83404
208-528-4256
Todd Williams
- Recruiting
Indiana University Health University Hospital
Indianapolis, Indiana, 46202
Monika Fischer
- Recruiting
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Corey Siegel
- Recruiting
United Medical Doctors - Los Alamitos
Los Alamitos, California, 90720
562-430-4449
Seyedehsan Navabi
- Recruiting
Gastroenterology Health Partners
Louisville, Kentucky, 40218
502-888-1988
Michael Krease
- Recruiting
Research Associates of South Florida - Miami - Southwest 8th Street
Miami, Florida, 33134
Alexander Veloso
- Recruiting
Gastro Health Research - Miami
Miami, Florida, 33176
Lukasz Kwapisz
- Recruiting
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, 53215
414-908-6500
Chetan Mittal
- Recruiting
Gastroenterology Health Partners
New Albany, Indiana, 47150
812-206-1702
Robert Luckett
- Recruiting
Lucida Clinical Trials
New Bedford, Massachusetts, 02740
Paul Sepe
- Recruiting
Care Access - New Iberia
New Iberia, Louisiana, 70560
813-851-0135
Son Nguyen
- Recruiting
New York Gastroenterology Associates
New York, New York, 10075
212-369-2490
Arthur Kornbluth
- Recruiting
California Medical Research Associates
Northridge, California, 91324
818-349-1979
Calin Arimie
- Recruiting
Orlando Health
Orlando, Florida, 32806
Udayakumar Navaneethan
- Recruiting
Digestive and Liver Center of Florida
Orlando, Florida, 32825
407-384-7388
Harinath Sheela
- Recruiting
Gastro Health Research - Pensacola
Pensacola, Florida, 32504
Frederic Newman
- Recruiting
Thomas Jefferson University - Medicine/GI and Hepatology
Philadelphia, Pennsylvania, 19107
215-955-8900
Priya Sehgal
- Recruiting
University Gastroenterology
Providence, Rhode Island, 02905
401-421-8800
Lisa Mueller
- Recruiting
Gastroenterology Research of San Antonio
San Antonio, Texas, 78229
210-615-3848
Charles Randall
- Recruiting
Southern Star Research Institute
San Antonio, Texas, 78229
210-581-2812
Jeff Bullock
- Recruiting
Louisiana Research Center
Shreveport, Louisiana, 71105
318-525-3233
John Provenza
- Recruiting
Washington University School of Medicine
St Louis, Missouri, 63110
Parakkal Deepak
- Recruiting
Precision Clinical Research
Sunrise, Florida, 33351
Jeffrey Schneider
- Recruiting
Washington Gastroenterology - Tacoma
Tacoma, Washington, 98405
253-272-5127
William Holderman
- Recruiting
Tyler Research Institute
Tyler, Texas, 75701
903-630-6211
George DuVall
- Recruiting
Gastro Intestinal Research Institute of Northern Ohio, LLC
Westlake, Ohio, 44145
Mousab Tabbaa
- Recruiting
Care Access - Yonkers
Yonkers, New York, 10701
Peter Wayne
Mexico16 sites, 16 recruiting
- Not yet recruiting
San Peregrino Unidad de Investigación
Aguascalientes, 20230
4493776500
Jovanni Toca Villegas
- Recruiting
Scientia Investigacion Clinica S.C.
Chihuahua City, 31207
Karina Ramirez
- Recruiting
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.
Ciudad Madero, 89440
Korely Trujillo
- Not yet recruiting
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
Durango, 34000
LUIS CARLOS DIAZ HERRERA
- Recruiting
Boca Clinical Trials Mexico S.C.
Guadajalara, 44600
3338306672
Christian Jaramillo Buendía
- Recruiting
Centro de Investigación Clínica y Medicina Traslacional (CIMeT)
Guadalajara, 44340
+52 3339869435
Jesús Alonso Valenzuela Pérez
- Not yet recruiting
Hospital General de Occidente
Guadalajara, 45170
Ana Turrado
- Not yet recruiting
Health Pharma Querétaro
Juriquilla, 76230
Amador Garcia
- Recruiting
Medical Care and Research SA de CV
Mérida, 97070
AXEL MENA QUINTERO
- Recruiting
Centro de Investigación Clinica Chapultepec
Mexico City, 04100
Elda Rodriguez Negrete
- Not yet recruiting
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, 14080
JESUS YAMAMOTO-FURUSHO
- Recruiting
Servicios de Oncología Médica Integral - Monterrey
Monterrey, 66220
Manuel Martinez Vazquez
- Recruiting
Centro de Investigacion Clinica Chapultepec
Morelia, 58260
4431478545
Araceli Muñoz Bautista
- Recruiting
Boca Clinical Trials Mexico SC
Puebla City, 72160
2229736952
Elias Ballesteros Suarez
- Recruiting
Clinical Research Institute S.C.
Tlalnepantla, 54055
52 55 53627780
Leticia Marin
- Not yet recruiting
FAICIC S. de R.L. de C.V.
Veracruz, 91900
2299327808
Aracely Cruz Palacios
Brazil15 sites, 15 recruiting
- Recruiting
NewData Clinical Research - Aracaju
Aracaju, 49075-000
+55 79 98825-9395
Alex Callado França
- Recruiting
L2IP - Instituto de Pesquisas Clínicas
Brasília, 70200730
6134454300
Luciana Teixeira de Campos
- Recruiting
Loema Instituto de Pesquisa Clinica
Campinas, 13092-133
19 3252-5611
Joaquim Simoes Neto
- Recruiting
Fundação Universidade de Caxias do Sul (FUCS)
Caxias do Sul, 95070-560
Eduardo Brambilla
- Recruiting
Centro Digestivo de Curitiba
Curitiba, 80430-180
+55 41 3322-1115
Odery Ramos Júnior
- Recruiting
Galileo Medical Research
Juiz de Fora, 36033-318
Julio Chebli
- Recruiting
Hospital de Clinicas de Porto Alegre
Porto Alegre, 90035-903
+5551999199815
Luciana Harlacher
- Recruiting
Hospital de Clínicas de Ribeirão Preto
Ribeirão Preto, 14051-140
1636022283
Rogerio Parra
- Recruiting
CLIAGEN Clínica de Atenção em Gastroenterologia, Especialidades e Nutrição
Salvador, 41500-300
55 71 99957 2121
Genoile Silva
- Recruiting
Pesquisare Saude
Santo André, 09080-110
ALEXANDER DE SA ROLIM
- Recruiting
CPQuali Pesquisa Clínica
São Paulo, 01228-000
+55 11 2776-6801
Alexandre de Sousa Carlos
- Recruiting
CEPIC - Centro Paulista de Investigação Clínica
São Paulo, 04266-010
Renata Lamanna
- Recruiting
Clínica Hepatogastro JK
São Paulo, 04543-011
5511999158070
Rodrigo Andrey Rocco
- Recruiting
CEDOES
Vitória, 29055450
5527988393435
Felipe Ferreira
- Recruiting
Integral Pesquisa e Ensino
Votuporanga, 15500-269
+5517997472217
HERLON VALÉRIO
Poland12 sites, 12 recruiting
- Recruiting
Medrise Sp. z o.o.
Lublin, 20-582
+48 795 404 502
Wit Danilkiewicz
- Recruiting
Twoja Przychodnia Opolskie Centrum Medyczne
Opole, 45-819
690548825
Agata Lukawska
- Recruiting
IRMED
Piotrkow Trybunalski, 97-300
Katarzyna Ostrowska
- Recruiting
Twoja Przychodnia PCM
Poznan, 60-324
+48 724 444 299
Ewa Furmanowska-Ladorska
- Recruiting
Uniwersyteckie Centrum Stomatologii i Medycyny Specjalistycznej
Poznan, 60-354
618547552
Piotr Eder
- Recruiting
Korczowski Bartosz, Gabinet Lekarski
Rzeszów, 35-302
604481752
Bartosz Korczowski
- Recruiting
Twoja Przychodnia SCM
Szczecin, 71-434
48 91 433 29 19
Beata Gawdis-Wojnarska
- Recruiting
NZOZ GynCentrum - Oddział Warszawa
Warsaw, 00-124
Alina Kurylowicz
- Recruiting
Vivamed Sp. z o.o.
Warsaw, 03-580
604422988
Robert Petryka
- Recruiting
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś
Warsaw, 04-501
500111648
Jaroslaw Kierkus
- Recruiting
Melita Medical
Wroclaw, 53-611
48660551155
Jaroslaw Leszczyszyn
- Recruiting
ETG Zamość
Zamość, 22-400
48606930022
Katarzyna Wojcik
France10 sites, 10 recruiting
- Recruiting
Clinique des Cèdres
Échirolles, 38130
Nicolas MATHIEU
- Recruiting
CHD Vendee
La Roche-sur-Yon, 85000
Astrid De Maissin
- Recruiting
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre
Le Kremlin-Bicêtre, 94270
Aurelien Amiot
- Recruiting
Chu Saint Eloi
Montpellier, 34295
33467330224
Anne Bozon
- Recruiting
Centres Médico Chirurgicaux - Clinique Ambroise Paré
Neuilly-sur-Seine, 92200
01 41 43 05 73
Xavier Treton
- Recruiting
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet
Nice, 06202
33492039367
Stephane Schneider
- Recruiting
Hôpital Saint Antoine
Paris, 75571
Julien Kirchgesner
- Recruiting
CHU Charles Nicolle
Rouen, 76031
Nicolas RICHARD
- Recruiting
Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord
Saint-Priest-en-Jarez, 42270
Mathilde Barrau
- Recruiting
CHU Rangueil
Toulouse, 31059
cyrielle Gilletta
Spain10 sites, 10 recruiting
- Recruiting
Centro Médico Teknon
Barcelona, 08022
Miquel Sans Cuffi
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
+34932746258
Natalia Borruel
- Recruiting
Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Arquitecto Marcide
Ferrol, 15405
981 336871
ANA ECHARRI PIUDO
- Recruiting
Hospital de Cabueñes
Gijón, 33394
Pilar Varela Trastoy
- Recruiting
Hospital General Universitario Gregorio Marañon
Madrid, 28028
Ignacio Marin Jimenez
- Recruiting
Hospital Universitario La Paz
Madrid, 28046
MARIA DOLORES MARTIN ARRANZ
- Recruiting
Hospital Universitario Central de Asturias
Oviedo, 33011
985107878
Ruth De Francisco
- Recruiting
Complejo Hospitalario de Navarra
Pamplona, 31009
848422391
CRISTINA RODRIGUEZ GUTIERREZ
- Recruiting
Hospital Universitario Virgen Macarena
Seville, 41009
0034955008800
Federico Argüelles-Arias
- Recruiting
Hospital Universitari i Politecnic La Fe
Valencia, 46026
961244055
Marisa Iborra Colomino
Italy9 sites, 9 recruiting
- Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Bologna, 40138
0512145312
Fernando Rizzello
- Recruiting
Ospedale Specializzato in Gastroenterologia "Saverio de Bellis"
Castellana Grotte, 70013
+39 0804994379
Mauro Mastronardi
- Recruiting
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, 20122
0255032141
Flavio Caprioli
- Recruiting
Ospedale San Raffaele
Milan, 20132
Silvio Danese
- Recruiting
Azienda Ospedale - Università Padova
Padova, 35128
+390498217749
Edoardo Savarino
- Recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa, 56124
Linda Ceccarelli
- Recruiting
Ospedale Di Circolo
Rho, 20017
02 99430.3264
Simone Saibeni
- Recruiting
Fondazione Policlinico Universitario Agostino Gemelli
Roma, 00168
0630154678
Franco Scaldaferri
- Recruiting
Humanitas
Rozzano, 20089
0282243263
Alessandro Armuzzi
Turkey (Türkiye)9 sites, 9 recruiting
- Recruiting
Gazi University Health Research and Application Center Gazi Hospital
Ankara, 06560
0 505 319 22 57
Tarkan Karakan
- Recruiting
Uludag Universitesi
Bursa, 16059
+90 532 301 22 52
Murat KIYICI
- Recruiting
Eskisehir Osmangazi University
Eskişehir, 26480
Tuncer Temel
- Recruiting
Mustafa Kemal Universitesi
Hatay, 31030
Mehmet Demir
- Recruiting
Bezmialem Vakf Üniversitesi
Istanbul, 34093
Metin Basaranoglu
- Recruiting
Ege Universitesi Hastanesi
Izmir, 35100
+90 505 782 38 08
Nalan Unal
- Recruiting
Kocaeli University Medical Faculty Hospital
İzmit, 41380
0090 505 877 48 21
Hasan Yilmaz
- Recruiting
Mersin University
Mersin, 33110
905326145276
Engin Altintas
- Recruiting
Antalya Egitim ve Arastırma Hastanesi
Muratpaşa, 07050
Ayhan Hilmi Cekin
Israel8 sites, 8 recruiting
- Recruiting
Assuta Ashdod Medical Center
Ashdod, 7747629
+9720723398277
Adi Lahat-Zok
- Recruiting
Rambam Health Care Campus
Haifa, 3109601
972-4-7772850
Roni Weisshof
- Recruiting
Edith Wolfson Medical Center
Holon, 5810001
97235028500
Eran Israeli
- Recruiting
Shaare Zedek Medical Center
Jerusalem, 9103102
+972 26666916
Benjamin Koslowsky
- Recruiting
Rabin Medical Center
Petah Tikva, 4941492
+97239377241 (5)
Irit Avni-Biron
- Recruiting
Sheba Medical Center
Ramat Gan, 5262100
0523894508
Asaf Levartovsky
- Recruiting
Sourasky Medical Center
Tel Aviv, 6423906
+97236973011
Nathaniel Cohen
- Recruiting
Yitzhak Shamir Medical Center
Tsrifin, 7033001
972-8-934-9793
EFRAT BROIDE
Canada7 sites, 7 recruiting
- Recruiting
Gastroenterology and internal medicine research institute
Edmonton, T5R 1W2
7804991192
Allen Lim
- Recruiting
London Health Sciences Centre
London, N6A 5W9
519-685-8500
Terry Ponich
- Recruiting
London Digestive Disease Institute
London, N6K 1M6
Vipul Jairath
- Recruiting
Clinique IMD
Montreal, H3H 1E8
514-798-0550
Waqqas Afif
- Not yet recruiting
The Ottawa Hospital - General Campus
Ottawa, K1H 8L6
Jeffrey McCurdy
- Recruiting
Vancouver General Hospital
Vancouver, V5Z 1M9
Sundeep Singh
- Recruiting
(G.I.R.I.) GI Research Institute Foundation
Vancouver, V5Z 2K5
Greg Rosenfeld
Belgium6 sites, 6 recruiting
- Recruiting
AZORG Campus Aalst-Moorselbaan
Aalst, 9300
053 72 44 28
Stijn Vanden Branden
- Recruiting
Université Libre de Bruxelles - Hôpital Erasme
Brussels, 1070
003225555422
Denis Franchimont
- Recruiting
AZ Groeninge Campus Kennedylaan
Kortrijk, 8500
+32 56 63 33 00
Wouter Van Moerkercke
- Recruiting
UZ Leuven
Leuven, 3000
+3216348856
João Guedelha Sabino
- Recruiting
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, 4000
+3243237256
Edouard Louis
- Recruiting
Clinical Chc Montlégia
Liège, 4000
+3243554211
Arnaud Colard
Czechia6 sites, 6 recruiting
- Recruiting
SurGal Clinic
Brno, 602 00
Jan Ulbrych
- Recruiting
Gastroenterologie
Hradec Králové, 500 02
+420607142114
Milan Siroky
- Recruiting
EndoArt
Ostrava, 710 00
00420602110107
Radka Koskova
- Recruiting
ResTrial GastroEndo s.r.o
Prague, 143 00
Ludek Hrdlicka
- Recruiting
ISCARE klinické centrum
Prague, 19000
+420 725 505 279
Milan Lukas
- Recruiting
Masarykova Nemocnice V Usti Nad Labem
Ústí nad Labem, 40113
420477112450
Michal Tichy
Denmark6 sites, 6 recruiting
- Recruiting
Aarhus Universitetshospital, Skejby
Aarhus, 8200
Anders Dige
- Recruiting
Rigshospitalet
Copenhagen, 2100
Anja Poulsen
- Recruiting
Herlev and Gentofte Hospital
Copenhagen, 2730
0045 38681848
Jacob Bjerrum
- Recruiting
Aalborg Universitetshospital, Syd
Gistrup, 9260
Henrik Jacobsen
- Recruiting
Odense Universitetshospital
Odense, 5000
Jens Kjeldsen
- Recruiting
Vejle Sygehus
Vejle, 7100
Maiken Jørgensen
Germany6 sites, 6 recruiting
- Recruiting
Universitätsklinikum Frankfurt Goethe-Universität
Frankfurt, 60590
069630187769
Irina Blumenstein
- Recruiting
Praxiszentrum für Gastroenterologie
Grevenbroich, 41515
02181475930
Axel Naumann
- Recruiting
Studiengesellschaft Mitteldeutschland GmbH
Halle, 06108
00493452997626
Lars Fechner
- Recruiting
Medizinische Hochschule Hannover
Hanover, 30625
05115329427
Ursula Seidler
- Recruiting
Eugastro GmbH
Leipzig, 04103
00493414935720
Ingolf Schiefke
- Recruiting
Klinikum Ernst von Bergmann
Potsdam, 14467
004933124136202
Daniel Baumgart
Romania6 sites, 6 recruiting
- Recruiting
Spitalul Județean de Urgență Bacău
Bacau, 600114
0740182009
ELENA POPOVICI
- Recruiting
Spitalul Clinic Colentina
Bucharest, 020125
0213152590
Bogdan Mateescu
- Recruiting
Spitalul Universitar de Urgență București
Bucharest, 050098
0722546405
Lucian Negreanu
- Recruiting
Constanta County Emergency Clinical Hospital Sf.Ap.Andrei
Constanța, 900591
+40744761454
Eugen Dumitru
- Recruiting
Spitalul Clinic Județean de Urgență
Craiova, 200642
40751268731
Dan Ionut Gheonea
- Recruiting
S.C Centrul de Gastroenterologie Dr. Goldis S.R.L
Timișoara, 300002
0040722410712
Adrian Goldis
Netherlands5 sites, 5 recruiting
- Recruiting
Amsterdam UMC, locatie VUmc
Amsterdam, 1081 HZ
31205666545
Mark Lowenberg
- Not yet recruiting
Radboudumc
Nijmegen, 6525 GA
+31 24 3619190
Marjolijn Duijvestein
- Not yet recruiting
Erasmus Medisch Centrum
Rotterdam, 3015 GD
+317030792
Annemarie de Vries
- Recruiting
Ikazia Ziekenhuis
Rotterdam, 3083 AN
0102975000
Geert Bezemer
- Recruiting
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX
0031887573618
Herma Fidder
Greece4 sites, 4 recruiting
- Recruiting
Evangelismos General Hospital of Athens
Athens, 106 76
NIKOLAOS VIAZIS
- Recruiting
Thoracic General Hospital of Athens "I Sotiria"
Athens, 115 27
+306976062713
Giorgos Bamias
- Recruiting
University General Hospital of Heraklion
Heraklion, 711 10
2810392037
Ioannis Koutroubakis
- Recruiting
Ippokrateio General Hospital of Thessaloniki
Thessaloniki, 54642
OLGA GIOULEME
Hungary4 sites, 4 recruiting
- Recruiting
Semmelweis Egyetem
Budapest, 1082
0036208250460
Pal Miheller
- Recruiting
Semmelweis Egyetem
Budapest, 1088
3612664616
Zsolt Tulassay
- Recruiting
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, 6725
Tamas Molnar
- Recruiting
CLINFAN Szolgáltató Kft
Szekszárd, 7100
+36302777114
Agnes Salamon
Slovakia4 sites, 4 recruiting
- Recruiting
Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
Banská Bystrica, 97517
421905838606
Jozef Balaz
- Recruiting
Cliniq s.r.o.
Bratislava, 81109
+421917752297
Tibor Hlavaty
- Recruiting
ENDOMED
Košice, 040 13
+421 905 271215
Miroslav Fedurco
- Recruiting
Gastro LM
Prešov, 080 01
+421905794001
Lubomir Mihalkanin
Austria3 sites, 3 recruiting
- Recruiting
Medizinische Universität Graz
Graz, 8036
Christoph Hoegenauer
- Recruiting
Medizinische Universitaet Innsbruck
Innsbruck, 6020
4351250481311
Robert Koch
- Recruiting
Medizinische Universität Wien
Vienna, 1090
004314040062450
Walter Reinisch
Bulgaria1 site, 1 recruiting
- Recruiting
University Hospital "St. Ivan Rilski"
Gorna Oryahovitsa, 5100
Ilko Kosturkov
Puerto Rico1 site, 1 recruiting
- Recruiting
CMRC Headlands, LLC
San Juan, 00918
Melvyn Acosta Febo
About this study
Official title: A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.
The maximum duration of this study is up to 61 weeks.
- Conditions
- Crohn's Disease, Obesity or Overweight
- Being tested
- Mirikizumab, Tirzepatide, Placebo
- Medical subject headings
- Crohn Disease, Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MirikizumabDrug
Also called LY3074828
Administered IV
MirikizumabDrug
Also called LY3074828
Administered SC
TirzepatideDrug
Also called LY3298176
Administered SC
PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Mirikizumab + Tirzepatide | Experimental | Mirikizumab administered intravenously (IV) then Mirikizumab administered subcutaneously (SC).
Tirzepatide administered SC. Receives: Drug: Mirikizumab; Drug: Tirzepatide |
| Mirikizumab + Placebo | Experimental | Mirikizumab administered IV then Mirikizumab administered SC. Placebo administered SC. Receives: Drug: Mirikizumab; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction
Percentage of participants who simultaneously achieve clinical remission by CDAI, endoscopic remission and at least 10% weight reduction.
Measured: Week 52
Secondary outcomes (6)
Percentage of Participants Who Simultaneously Achieve Clinical Remission by CDAI and Endoscopic Remission
Percentage of participants who simultaneously achieve clinical remission by CDAI and endoscopic remission.
Measured: Week 24, 52
Percentage of Participants Who Achieved Maintenance of Clinical Remission by CDAI
Percentage of participants who achieve maintenance of clinical remission by CDAI.
Measured: Week 52
Percentage of Participants Who Achieved Maintenance of Endoscopic Remission
Percentage of participants who achieve maintenance of endoscopic remission.
Measured: Week 52
Percentage of Participants Who Achieve Corticosteroid-free Clinical Remission by CDAI Among Participants Who Used Corticosteroids at Baseline
Percentage of participants who achieve corticosteroid-free clinical remission by CDAI among participants who used corticosteroids at baseline.
Measured: Week 52
Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)
Change from baseline in inflammatory bowel disease questionnaire (IBDQ).
Measured: Baseline, Week 52
Percentage of Participants Who Achieve at Least a 10% Reduction in Body Weight
Percentage of participants who achieve at least a 10% reduction in body weight.
Measured: Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2025
- Study start26 Jun 2025
- Primary completionMay 2028 (estimated)
- Study completionMay 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn's DiseaseStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 290 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06937099
- Sponsor's protocol ID
- 27281
- Other IDs
- 2024-520210-21-00, I6T-MC-AMCE
- Acronym
- COMMIT-CD
- Status last verified
- Nov 2026
- First submitted
- 18 Apr 2025
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- ClinicalTrials.gov ID
- NCT06937099
- Acronym / sponsor ID
- COMMIT-CD / 27281
- Conditions
- Crohn's Disease, Obesity or Overweight
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 290 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 26 Jun 2025 (actual)
- Primary completion
- May 2028 (estimated)
- Study completion
- May 2028 (estimated)
- First posted
- 22 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight.
The maximum duration of this study is up to 61 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mirikizumab + Tirzepatide | Experimental | Drug: Mirikizumab, Drug: TirzepatideMirikizumab administered intravenously (IV) then Mirikizumab administered subcutaneously (SC). Tirzepatide administered SC. |
| Mirikizumab + Placebo | Experimental | Drug: Mirikizumab, Drug: PlaceboMirikizumab administered IV then Mirikizumab administered SC. Placebo administered SC. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Have a confirmed diagnosis of Crohn's disease (CD) or perianal fistulizing CD
- Have obesity body mass index 30 kilograms per meter squared (BMI ≥30 kg/m²), or overweight (BMI ≥27 kg/m2 to <30 kg/m²) and in the presence of at least 1 weight-related comorbid conditions:
- Have moderately to severely active CD defined by a CDAI score of at least 220 at baseline.
- Have a centrally read Simple Endoscopic Score for Crohn's Disease (SES-CD) score ≥6 for patients with ileal-colonic or ≥4 for patients with isolated ileal disease within 21 days before the first dose of study treatment.
- Participants with a history of CD for ≥8 years involving only or predominantly the colon must have documented negative results for colorectal dysplasia and cancer within 1 year prior to baseline.
Key exclusion criteria (9 listed)
- Have a current diagnosis of Ulcerative Colitis (UC), inflammatory bowel disease-unclassified (formerly known as indeterminate colitis), or primary sclerosing cholangitis.
- Have more than 2 missing segments of the following 5 segments: terminal ileum, ·right colon, transverse colon, ·left colon, and rectum.
- Currently have or are suspected to have an abscess.
- Have a stoma, ileoanal pouch, or ostomy.
- Have a history of more than 3 small bowel resections, total resection of small bowel greater than 100 centimeters (cm), diagnosis of short bowel syndrome, or any intestinal or non-intestinal intra-abdominal surgery within 3 months of baseline.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MirikizumabAlso: LY3074828Administered IV | Drug | Mirikizumab + Placebo, Mirikizumab + Tirzepatide |
| MirikizumabAlso: LY3074828Administered SC | Drug | Mirikizumab + Placebo, Mirikizumab + Tirzepatide |
| TirzepatideAlso: LY3298176Administered SC | Drug | Mirikizumab + Tirzepatide |
| PlaceboAdministered SC | Drug | Mirikizumab + Placebo |
Primary outcome
Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction
Time frame: Week 52
Percentage of participants who simultaneously achieve clinical remission by CDAI, endoscopic remission and at least 10% weight reduction.
6 secondary outcomes
Percentage of Participants Who Simultaneously Achieve Clinical Remission by CDAI and Endoscopic Remission
Time frame: Week 24, 52
Percentage of Participants Who Achieved Maintenance of Clinical Remission by CDAI
Time frame: Week 52
Percentage of Participants Who Achieved Maintenance of Endoscopic Remission
Time frame: Week 52
Percentage of Participants Who Achieve Corticosteroid-free Clinical Remission by CDAI Among Participants Who Used Corticosteroids at Baseline
Time frame: Week 52
Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)
Time frame: Baseline, Week 52
Percentage of Participants Who Achieve at Least a 10% Reduction in Body Weight
Time frame: Week 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Crohn's Disease
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
183 sites in 22 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Mirikizumab and Tirzepatide in people with Crohn's Disease and Obesity or Overweight, run by Eli Lilly and Company at 183 sites in 22 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 183 sites in United States, Mexico, Brazil, Poland, France and 17 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction (time frame: Week 52). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.